Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Sutro Biopharma Inc (Sutro Biopharma) is a clinical-stage oncology company that carries out the discovery and development of cancer therapeutics. Its pipeline products include STRO-004, STRO-006, STRO-227 and STRO-00Y which treats solid tumors. Sutro Biopharma other pipeline products include VAX-24 and VAX-31 for invasive pneumococcal disease. The company includes antibody-drug conjugates (ADCs), XpressCF and XpressCF+ technology platforms. It offers drug discovery and drug development capabilities. The company works in collaboration with pharmaceutical and biotechnology companies. Sutro Biopharma is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
111 Oyster Point Blvd., South San Francisco, California, 94080
Website
www.sutrobio.com
Telephone
1 650 8816500
No of Employees
137
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
STRO (NASD)
Revenue (2024)
$102.5M
65.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
16%
(2024 vs 2023)
Market Cap*
$387.8M
Net Profit Margin (2024)
XYZ
49.1%
(2024 vs 2023)
* As of and is in US$
Products and Services
| Products | Brands |
|---|---|
| Pipeline | XpressCF |
| STRO-004: Solid Tumors | XpressCF+ |
| STRO-006: Solid Tumors | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In July, the company entered into a partnership with the U.S. Food and Drug Administration to develop reference materials for enhancing ADC drug development standards using its XpressCF technology. |
| 2024 | Contracts/Agreements | In June, the company entered into a partnership with VGXI to assist the clinical production of luveltamab tazevibulin. |
| 2024 | Contracts/Agreements | In April, the company entered into an agreement with Ipsen Pharma to develop and commercialize STRO-003. |
Competitor Comparison
| Key Parameters | Sutro Biopharma Inc | ADC Therapeutics SA | Mersana Therapeutics Inc | Ambrx Biopharma Inc | Aprea Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | United States of America | United States of America |
| City | South San Francisco | Epalinges | Cambridge | La Jolla | Doylestown |
| State/Province | California | - | Massachusetts | California | Pennsylvania |
| No. of Employees | 137 | 188 | 102 | - | 8 |
| Entity Type | Public | Public | Private | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Connie Matsui | Chairman | Executive Board | 2019 | 72 |
| Jane Chung | Chief Executive Officer; Director | Executive Board | 2025 | 55 |
| Gregory Chow | Chief Financial Officer | Senior Management | 2025 | 53 |
| David Pauling | General Counsel; Chief Administrative Officer | Senior Management | 2025 | 52 |
| Hans-Peter Gerber, Ph.D. | Chief Scientific Officer | Senior Management | 2023 | 63 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer